Interferon γ, a possible therapeutic approach for late-stage prostate cancer?

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 2843-2849

  Hastie, Claire ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Annexin; Cancer; Cytokine; Gp96; Prostate; Review

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; GAMMA INTERFERON; GLYCOPROTEIN GP 96; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HORMONE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LIPOCORTIN 2; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RETINOIC ACID; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D DERIVATIVE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CELL THERAPY; CLINICAL TRIAL; DRUG INHIBITION; FATIGUE; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; MALAISE; MELANOMA; METASTASIS; NAUSEA; NEUROTOXICITY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; VOMITING; WEIGHT REDUCTION;

ANIMALS; HUMANS; INTERFERON-GAMMA; MALE; PROSTATIC NEOPLASMS;

EID: 55749087009     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Stamey TA, McNeal JE, Yemoto CM, Sigal BM and Johnstone IM: Biological determinants of cancer progression in men with prostate cancer. JAMA 281: 1395-400, 1999.
2. Mazhar D and Waxman J: Prostate cancer. Postgrad Med J 78: 590-5, 2002.
3. Wilkinson S and Chodak G: An evaluation of intermediate-dose ketoconazole in hormone-refractory prostate cancer. Eur Urol 45: 581-584; discussion 585, 2004.
4. Oh WK, George DJ and Tay MH: Response to docetaxel/ carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. Clin Prostate Cancer 4: 61-64, 2005.
5. Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M et al: Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res 14: 2437-2443, 2008.
6. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM and Feldman D: Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res 22(Suppl 2): V74-80, 2007.
7. Lee D: New treatment modalities for hormone-resistant prostate cancer. Clin Prostate Cancer 1: 139-141, 2002.
8. Cai Y, Lee YF, Li G, Liu S, Bao BY, Huang J, Hsu CL and Chang C: A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. Int J Cancer 123: 195-201, 2008.
9. Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C and Dalgleish AG: Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94: 412-418, 2004.
10. Ward JE and McNeel DG: GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther 7: 1893-1902, 2007.
11. Patel PH and Kockler DR: Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 42: 91-98, 2008.
12. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J et al: Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53: 109-117, 2002.
13. Hudes GR: Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs 20: 159-172, 2002.
14. Sternberg CN: What's new in the treatment of advanced prostate cancer? Eur J Cancer 39: 136-146, 2003.
15. Hobeika AC, Subramaniam PS and Johnson HM: IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 14: 1165-1170, 1997.
16. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, Sweeney P, Mian B, Fan D, Shepherd D et al: Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res 62: 5720-5726, 2002.
17. Tsai SY, Hsieh TC, Ardelt B, Darzynkiewicz Z and Wu JM: Combined effects of onconase and IFN-beta on proliferation, macromolecular syntheses and expression of STAT-1 in JCA-1 cancer cells. Int J Oncol 20: 891-896, 2002.
18. Fang P, Hwa V and Rosenfeld RG: Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp Cell Res 312: 1229-1239, 2006.
19. Bauer JA, Morrison BH, Grane RW, Jacobs BS, Borden EC and Lindner DJ: IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis. J Interferon Cytokine Res 23: 3-10, 2003.
20. Harris DT, Matyas GR, Gomella LG, Talor E, Winship MD, Spitler LE and Mastrangelo MJ: Immunologic approaches to the treatment of prostate cancer. Semin Oncol 26: 439-447, 1999.
21. Kramer G, Steiner GE, Sokol P, Handisurya A, Klingler HC, Maier U, Foldy M and Marberger M: Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer. J Interferon Cytokine Res 21: 475-484, 2001.
22. Selleck WA, Canfield SE, Hassen WA, Meseck M, Kuzmin AI, Eisensmith RC, Chen SH and Hall SJ: IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach. Mol Ther 7: 185-192, 2003.
23. Street SE, Cretney E and Smyth MJ: Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97: 192-197, 2001.
24. Angelucci C, Iacopino F, Ferracuti S, Urbano R and Sica G: Recombinant human IFN-beta affects androgen receptor level, neuroendocrine differentiation, cell adhesion, and motility in prostate cancer cells. J Interferon Cytokine Res 27: 643-652, 2007.
25. Kuratsukuri K, Nishisaka N, Jones RF, Wang CY and Haas GP: Clinical trials of immunotherapy for advanced prostate cancer. Urol Oncol 5: 265-273, 2000.
26. Cao G, Su J, Lu W, Zhang F, Zhao G, Marteralli D and Dong Z: Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 8: 497-505, 2001.
27. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K and Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114: 560-568, 2004.
28. Dunn GP, Sheehan KC, Old LJ and Schreiber RD: IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 65: 3447-3453, 2005.
29. Blades RA, Keating PJ, McWilliam LJ, George NJ and Stern PL: Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46: 681-686; discussion 686-687, 1995.
30. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T, Pagano F et al: Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201: 1257-1268, 2005.
31. Ambrus JL, Sr., Dembinski W, Ambrus JL Jr, Sykes DE, Akhter S, Kulaylat MN, Islam A and Chadha KC: Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma. Cancer 98: 2730-2733, 2003.
32. Ronchese F, Prasad S and Ritchie DS: Tumour antigens on tap. Lancet 360: 268, 2002.
33. Basrawala Z, Alimirah F, Xin H, Mohideen N, Campbell SC, Flanigan RC and Choubey D: Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells. Oncogene 25: 2812-2817, 2006.
34. Strannegard O, Thoren FB and Lundgren E: Interferon-alpha can improve the prognosis in high-risk melanoma. Combination of surgery, cytostatics and natural IFN-alpha doubled the survival rate. Lakartidningen 105: 358-361, 2008.
35. Feldman DR, Kondagunta GV, Schwartz L, Patil S, Ishill N, DeLuca J, Russo P and Motzer RJ: Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 6: 25-30, 2008.
36. Auranen A and Grenman S: Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer. Int J Gynecol Cancer 18(Suppl 1): 44-46, 2008.
37. Qian YB, Zhang JB, Wu WZ, Fang HB, Jia WD, Zhuang PY, Zhang BH, Pan Q, Xu Y, Wang L et al: P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer 107: 1562-1569, 2006.
38. van Haelst-Pisani CM, Richardson RL, Su J, Buckner JC, Hahn RG, Frytak S, Kvols LK and Burch PA: A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer. Cancer 70: 2310-2312, 1992.
39. Maffezzini M, Simonato A and Fortis C: Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 28: 282-286, 1996.
40. Thalasila A, Poplin E, Shih J, Dvorzhinski D, Capanna T, Doyle-Lindrud S, Beers S, Goodin S, Rubin E and DiPaola RS: A phase I trial of weekly paclitaxel, 13-cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies. Cancer Chemother Pharmacol 52: 119-24, 2003.
41. Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R and Logothetis CJ: The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. J Urol 153: 1587-1591, 1995.
42. Lee J, Wang A, Hu Q, Lu S and Dong Z: Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice. Int J Oncol 29: 1405-1412, 2006.
43. Bulbul MA, Huben RP and Murphy GP: Interferon-beta treatment of metastatic prostate cancer. J Surg Oncol 33: 231-233, 1986.
44. Deb DK, Sassano A, Lekmine F, Majchrzak B, Verma A, Kambhampati S, Uddin S, Rahman A, Fish EN and Platanias LC: Activation of protein kinase C delta by IFN-gamma. J Immunol 171: 267-273, 2003.
45. Aboagye-Mathiesen G, Ebbesen P, von der Maase H and Celis JE: Interferon gamma regulates a unique set of proteins in fresh human bladder transitional cell carcinomas. Electrophoresis 20: 344-348, 1999.
46. Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM and Gao WQ: Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci USA 99: 2830-2835, 2002.
47. Nagano K, Masters JR, Akpan A, Yang A, Corless S, Wood C, Hastie C, Zvelebil M, Cramer R and Naaby-Hansen S: Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 23: 1693-1703, 2004.
48. Lee KY, Geng H, Ng KM, Yu J, van Hasselt A, Cao Y, Zeng YX, Wong AH, Wang X, Ying J et al: Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene 27: 5267-5276, 2008.
49. Bacso Z, Bene L, Damjanovich L and Damjanovich S: INF-gamma rearranges membrane topography of MHC-I and ICAM-1 in colon carcinoma cells. Biochem Biophys Res Commun 290: 635-640, 2002.
50. Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, deKernion JB and Belldegrun AS: In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 77: 1862-1872, 1996.
51. Zhao P, Zhu YH, Wu JX, Liu RY, Zhu XY, Xiao X, Li HL, Huang BJ, Xie FJ, Chen JM et al: Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth. Life Sci 81: 695-701, 2007.
52. Matin SF, Rackley RR, Sadhukhan PC, Kim MS, Novick AC and Bandyopadhyay SK: Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res 61: 2261-2266, 2001.
53. Nanus DM, Geng Y, Shen R, Lai HK, Pfeffer SR and Pfeffer LM: Interaction of retinoic acid and interferon in renal cancer cell lines. J Interferon Cytokine Res 20: 787-794, 2000.
54. Wu WZ, Sun HC, Gao YQ, Li Y, Wang L, Zhou K, Liu KD, Iliakis G and Tang ZY: Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells. Oncology 67: 428-440, 2004.
55. Wong LH, Hatzinisiriou I, Devenish RJ and Ralph SJ: IFN-gamma priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs. J Immunol 160: 5475-5484, 1998.
56. Chen X, Ding Y, Liu CG, Mikhail S and Yang CS: Overexpression of glucose-regulated protein 94 (Grp94) in esophageal adenocarcinomas of a rat surgical model and humans. Carcinogenesis 23: 123-130, 2002.
57. 2+ increases and cell death. J Biol Chem 273: 12858-12862, 1998.
58. Goyos A, Guselnikov S, Chida AS, Sniderhan LF, Maggirwar SB, Nedelkovska H and Robert J: Involvement of nonclassical MHC class Ib molecules in heat shock protein-mediated antitumor responses. Eur J Immunol 37: 1494-1501, 2007.
59. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, Udono H and Srivastava PK: Heat-shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 186: 1315-1322, 1997.
60. Suriano R, Ghosh SK, Ashok BT, Mittelman A, Chen Y, Banerjee A and Tiwari RK: Differences in glycosylation patterns of heat shock protein, gp96: implications for prostate cancer prevention. Cancer Res 65: 6466-7645, 2005.
61. Cho NH, Choi CY and Seong SY: Down-regulation of gp96 by Orientia tsutsugamushi. Microbiol Immunol 48: 297-305, 2004.
62. Falcone DJ, Borth W, Khan KM and Hajjar KA: Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II. Blood 97: 777-784, 2001.
63. Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, Kamada K, Naito A, Hirao S and Nakajima Y: Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 92: 1419-1426, 2001.
64. Mai J, Waisman DM and Sloane BF: Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 1477: 215-330, 2000.
65. Wu W, Tang X, Hu W, Lotan R, Hong WK and Mao L: Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis 19: 319-326, 2002.
66. Brownstein C, Deora AB, Jacovina AT, Weintraub R, Gertler M, Khan KM, Falcone DJ and Hajjar KA: Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 103: 317-324, 2003.
67. Mai J, Waisman DM and Sloane BF: Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 1477: 215-330, 2000.
68. Kirshner J, Schumann D and Shively JE: CEACAM1, a cell-cell adhesion molecule, directly associates with annexin II in a three-dimensional model of mammary morphogenesis. J Biol Chem 278: 50338-50345, 2003.
69. Chung CY and Erickson HP: Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol 126: 539-648, 1994.
70. Choi S, Kobayashi M, Wang J, Habelhah H, Okada F, Hamada J, Moriuchi T, Totsuka Y and Hosokawa M: Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin. Clin Exp Metastasis 18: 45-50, 2000.
71. Sharma MC and Sharma M: The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target. Curr Pharm Des 13: 3568-3575, 2007.
72. Sehgal PB, Guo GG, Shah M, Kumar V and Patel K: Cytokine signaling: STATS in plasma membrane rafts. J Biol Chem 277: 12067-12074, 2002.
73. Yedavelli SP, Guo L, Daou ME, Srivastava PK, Mittelman A and Tiwari RK: Preventive and therapeutic effect of tumor-derived heat-shock protein, gp96, in an experimental prostate cancer model. Int J Mol Med 4: 243-248, 1999.